Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP, John M. Alvarez,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma Dean A. Fennell, PhD, FRCP,

National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma Vivek Verma, MD, Christopher A. Ahern,

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA, Eric.

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD

Pleural Well-Differentiated Papillary Mesothelioma: A Case Report

A Phase II Study of PF in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207 Paul Wheatley-Price, MBChB, MD, Quincy Chu,

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma Isabelle Opitz, MD, Martina Friess,

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

John E. Pilling, FRCS (CTh), Michael E

Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy Hasan Fevzi Batirel, MD,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy

A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis Fraser J.H. Brims, MD, Tarek M. Meniawy,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma Fauzia Shaikh, MD, Marjorie G. Zauderer,

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus

Volume 5, Issue 4, Pages (April 2018)

Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non–Small-Cell Lung Cancer Shankar Siva, MBBS, FRANZCR, Jason Callahan, BAppSci,

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients Raja.

Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural.

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study Gunnar Hillerdal, MD, PhD, Jens.

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer? Esther Dajczman, RN, MScA, Goulnar Kasymjanova, MD, PhD,

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

It’s All in the “Swerve of the Curve”

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc.

Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma Zacariah E. Labby, PhD, Samuel G. Armato, PhD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Ethnic Differences in the Management of Lung Cancer in New Zealand

International Thymic Malignancies Interest Group: A Way Forward

Linda L. Garland, MD, Kari Chansky, MS, Antoinette J

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

A Pathological Complete Response in Malignant Pleural Mesothelioma after Combination Chemotherapy with Carboplatin and Pemetrexed Steven Chuan-Hao Kao,

Lung Cancer in New Zealand: Patterns of Secondary Care and Implications for Survival Wendy Stevens, MBBS, Graham Stevens, MD, FRANZCR, John Kolbe, MBBS,

David James Pinato, MD, MRes, Francesco A

Raja M. Flores, MD The Journal of Thoracic and Cardiovascular Surgery

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.

Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer: A SEER Database Analysis Attila Dubecz, MD, Isabell Gall, MD, Norbert Solymosi,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Debby P. M. van den Bogaert, MD, Ellen M

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

A Review of First-Line Treatment for Small-cell Lung Cancer

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP, John M. Alvarez, MBBS, FRACS, Jenny Ma Wyatt, MBBS, FRCPA, Sean Bydder, MBChB, FRANZCR, Michael Millward, FRACP, Michael Byrne, MBBS, BMed Sci, FRACP, Arthur W. (Bill) Musk, MBBS, MD, MSc, FRACP, FAFOEM, Anna K. Nowak, MBBS, FRACP, PhD Journal of Thoracic Oncology Volume 4, Issue 8, Pages 1010-1016 (August 2009) DOI: 10.1097/JTO.0b013e3181ae25bf Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Flow chart of workup and treatment of eligible patients referred for TMT. MDM, multidisciplinary meeting; MPM, malignant pleural mesothelioma; TMT, trimodality therapy; EPP, extrapleural pneumonectomy. Journal of Thoracic Oncology 2009 4, 1010-1016DOI: (10.1097/JTO.0b013e3181ae25bf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Flow chart of patient progression. TMT, trimodality therapy; EPP, extrapleural pneumonectomy. Journal of Thoracic Oncology 2009 4, 1010-1016DOI: (10.1097/JTO.0b013e3181ae25bf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier survival curves of survival after date of diagnosis for EPP group (n = 18) and non-EPP group (n = 18). EPP, extrapleural pneumonectomy. Journal of Thoracic Oncology 2009 4, 1010-1016DOI: (10.1097/JTO.0b013e3181ae25bf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions